DCK and acute myeloid leukemia: DCK typically catalyzes the rate-limiting step of the formation of deoxynucleoside triphosphates, and the present SNP (rs4643786, 948T>C) is related to lower DCK expression in lymphocytes.[29] Consistent with this finding, 948C carriers with AML receiving topoisomerase inhibitors had superior response than those who carried 948TT [30].